Analysts expect Allena Pharmaceuticals Inc (NASDAQ:ALNA) to announce earnings per share (EPS) of ($0.51) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Allena Pharmaceuticals’ earnings, with estimates ranging from ($0.57) to ($0.40). Allena Pharmaceuticals posted earnings of ($0.46) per share in the same quarter last year, which would suggest a negative year over year growth rate of 10.9%. The business is scheduled to issue its next quarterly earnings report on Thursday, March 5th.
Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Allena Pharmaceuticals.
Allena Pharmaceuticals (NASDAQ:ALNA) last issued its earnings results on Wednesday, November 13th. The company reported ($0.57) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.08).
Shares of ALNA traded up $0.03 during trading hours on Thursday, hitting $1.67. The stock had a trading volume of 540,400 shares, compared to its average volume of 797,266. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.96 and a quick ratio of 6.80. The firm has a market capitalization of $38.48 million, a P/E ratio of -0.97 and a beta of 2.02. The firm has a 50 day simple moving average of $4.32 and a 200-day simple moving average of $4.52. Allena Pharmaceuticals has a 1-year low of $1.55 and a 1-year high of $10.66.
A number of institutional investors have recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. grew its stake in Allena Pharmaceuticals by 17.0% in the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 41,587 shares of the company’s stock valued at $169,000 after buying an additional 6,030 shares in the last quarter. Wedbush Securities Inc. grew its stake in Allena Pharmaceuticals by 66.6% in the 3rd quarter. Wedbush Securities Inc. now owns 25,650 shares of the company’s stock valued at $101,000 after buying an additional 10,250 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Allena Pharmaceuticals during the 2nd quarter valued at $116,000. Susquehanna International Group LLP purchased a new position in shares of Allena Pharmaceuticals during the 2nd quarter valued at $137,000. Finally, Paloma Partners Management Co purchased a new position in shares of Allena Pharmaceuticals during the 2nd quarter valued at $212,000. Institutional investors and hedge funds own 65.40% of the company’s stock.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Featured Article: What causes a yield curve to invert?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.